Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Miller

Pain Medicine Davenport, IA Medical Doctor

NPI 1265439947 CMS profile 147516

3400 Dexter Ct, Davenport, IA 52807

Open in the dashboard

General payments

$4,055

79 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Miller of Davenport, IA is reported in the CMS Open Payments database as having received $4,055 across 79 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $333 13
2024 General $1,206 23
2023 General $226 5
2022 General $1,878 17
2021 General $48 3
2019 General $363 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Miller
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Timothy Miller were reported at $333. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Timothy Miller Pain Medicine median Middle half National median
2019 $363 $506 $144–$1,566 $163
2020 $0 $315 $96–$934 $114
2021 $48 $452 $134–$1,237 $132
2022 $1,878 $475 $124–$1,407 $149
2023 $226 $480 $136–$1,384 $160
2024 $1,206 $521 $164–$1,511 $164
2025 $333 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,874 30 payments
  2. SPR Therapeutics, Inc $257 6 payments
  3. Nevro Corp. $191 8 payments
  4. Medtronic USA, Inc. $158 3 payments
  5. Pfizer Inc. $83 6 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $73 1 payment
  7. Biodelivery Sciences International, Inc. $70 5 payments
  8. Daiichi Sankyo Inc. $64 4 payments
  9. Vertex Pharmaceuticals Incorporated $50 3 payments
  10. Abbott Laboratories $48 2 payments
  11. Other $188 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,435 71 payments
  2. Travel and Lodging $1,620 8 payments
Products named General payments · program years 2019–2025
  1. Superion Indirect Decompression System $1,718 11 payments
  2. SPRINT PNS System $257 6 payments
  3. ADAPTIVESTIM $141 2 payments
  4. Senza $117 4 payments
  5. Intracept $96 1 payment
  6. NURTEC ODT $73 1 payment
  7. LYRICA $66 5 payments
  8. Omnia $60 3 payments
  9. BUNAVAIL 2.1 mg 30-count box $56 4 payments
  10. BUNAVAIL 2.1 mg single pouch $56 4 payments
  11. Other $719 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

3,219

Median for Interventional Pain Management: 1,220

Drug cost

$43,064

Median for Interventional Pain Management: $39,344

Branded share of claims

35.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 864 $12,048
Tramadol Hcl Generic 919 $7,998
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 198 $5,136
Gabapentin Generic 275 $4,232
Pregabalin Generic 212 $4,119
Fentanyl Generic 15 $2,053
Morphine Sulfate Er Morphine Sulfate Brand 41 $949
Baclofen Generic 81 $899
Acetaminophen-Codeine Acetaminophen With Codeine Brand 44 $838
Oxycodone Hcl Generic 41 $614

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$152,433

Of which drugs: $797

Medicare patients

700

Average age 73

Services billed

2,885

411 women, 289 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Diabetes 30%
Depression 28%
Ischemic heart disease 22%
Chronic kidney disease 20%
COPD 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 88 972 $732
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 83 228 $65

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record